National Heart, Lung, and Blood Institute / National Institutes of Health Signs Clinical Trial Agreement with Vascarta Inc. to Perform Phase 1 Clinical Study of VAS-101 in Sickle Cell Disease
Under the agreement, the National Heart, Lung, and Blood Institute / National Institutes of Health will perform a human phase I clinical trial ofVascarta's VAS-101 (Vasceptor®; topical curcumin gel) in Sickle Cell Disease (SCD). The clinical trial is anticipated to be initiated later this year by NHLBI under the medical supervision of principal investigator, Dr. […]